Chromatin remodelling complexes alter the structure of chromatin and have central roles in all DNAtemplated activities, including regulation of gene expression and DNA repair. Mutations in subunits of the PBAF (polybromo/Brg1-associated factor) or SWI/SNF-B remodelling complex, including BAF180, are frequently associated with cancer. There are six potential acetyl-lysine-binding BDs (bromodomains) in BAF180, which may function to target the PBAF complex to promoters or sites of DNA repair. In the present review, we discuss what is currently known about the BDs of BAF180 and their potential significance in cancer.
BAF180 is a subunit of PBAF (polybromo/Brg1-associated factor)
DNA in enukaryotes is packaged into chromatin, the basic unit of which is the nucleosome, itself composed of ∼ 147 bp of DNA wrapped around a histone octamer containing two copies of each of H2A, H2B, H3 and H4. Access to chromatin can be regulated by two classes of enzymes: those that post-translationally modify histones and those that remodel chromatin by exchanging histones and sliding, repositioning and evicting nucleosomes [1, 2] .
Chromatin remodelling complexes are critical for mediating the processes of transcription, replication, DNA repair and recombination. Remodellers are generally large, multiprotein complexes containing a catalytic, DNA-dependent ATPase, which is a member of the Snf2 superfamily. The other subunits frequently contain domains that specifically interact with chromatin, such as BDs (bromodomains), chromodomains and PHD (plant homeodomain) fingers.
In humans, the SWI/SNF family of chromatin remodelling complexes is formed of distinct complexes that differ in their overall subunit composition; although there is a large set of subunits common to all (as shown in Table 1 ). The BAF (or SWI/SNF-A) complex contains either the BRG1 or hBRM catalytic subunit, as well as the ARID1 (or BAF250) protein. PBAF (or SWI/SNF-B) in contrast, contains only the BRG1 subunit, as well as three unique component proteins: BRD7, BAF180 and BAF200 [3] [4] [5] .
The gene encoding BAF180 (PBRM1) has been shown to be frequently mutated in cancer, and in one recent study of renal cell carcinomas, this was the case in approximately 40% of tumour samples examined [6] . This is a striking number and raises the question of what cellular function BAF180 normally provides to prevent tumorigenesis in cells.
In order to begin to address this, we need to understand the mechanistic role of BAF180 within the context of the PBAF complex.
The BAF180 protein contains six BDs followed sequentially by two BAH (bromo-adjacent homology) domains and an HMG (high-mobility group) box (see Figure 1A) . BDs in other chromatin remodelling and modifying complexes are often involved in binding to acetylated histones. BAF180 may therefore function as a 'targeting subunit' for the PBAF complex, defining its transcriptional specificity [7] . In the present paper, we focus on what is currently known about the BDs of BAF180 and the mutations identified in these domains relevant to cancer.
Binding targets of BAF180 BDs
The BD functions as an acetyl-lysine-binding domain [8] , the structure of which comprises an atypical left-handed four-helix bundle, with the binding pocket formed by two connecting loops (see Figure 2A) . Although BDs are intrinsically capable of binding to any acetylated substrate, it seems reasonable to assume that the BAF180 BDs will bind to acetylated histones and somehow facilitate the recruitment, targeting, retention or orientation of the PBAF complex on chromatin. To date, there have been two studies examining the ability of the BAF180 BDs to bind defined acetylated histone peptides [9, 10] . In each case, all six BDs (BD1-BD6) were individually expressed and purified, then used for in vitro binding assays. However, these studies came to very different conclusions.
Chandrasekaran and Thompson used the technique of fluorescence anisotropy to determine equilibrium dissociation constants, testing histone H3 peptides containing single acetylation sites on either Lys 4 , Lys 9 , Lys 14 , Lys 18 or Lys 23 . In doing so, they found that the individual BAF180 BDs displayed a distinct pattern of affinity for the each of the acetylated peptides with a single preferred peptide for the first five BDs (BD1-H3K4Ac, BD2-H3K9Ac, BD3-H3K9Ac, BD4-H3K23Ac and BD5-H3K14Ac). The sixth BD (BD6) was not found to have a noticeable preference for any of the H3 peptides [9] . In the second study, Zhou and co-workers tested each of the six BDs against mono-acetylated peptides derived from the four core histones using a dot blot assay [10] . Instead of calculating dissociation constants, they classified binding affinity as 'high', 'medium', 'low' or 'negative' by quantification of signal intensity. Again, each BD displayed a unique pattern of binding preference to each of the acetylated peptides, yet surprisingly there was no consensus with the results published in the previous study. The peptides that were scored 'high' in their assay were H3K36Ac for BD1, H3K14Ac and H2BK116Ac for BD2, H3K115Ac, H4K12Ac, H2BK15Ac and H2BK120Ac for BD3, H3K14Ac and H3K115Ac for BD4, H3K36Ac for BD5 and H2BK24Ac and H2BK116Ac for BD6. Notably, the top hits from the fluorescence anisotropy study for BDs BD2, BD3, BD4 and BD5 all scored 'negative' in the dot blot study [9, 10] .
It is possible that the different methodologies employed would account for the discrepancy between the two studies, but it certainly leaves the question of what are the physiological targets of the BAF180 BDs wide open.
In yeast, the homologous complex of PBAF is RSC (remodelling the structure of chromatin), but interestingly there are instead three separate subunits (Rsc1, Rsc2 and Rsc4), which in combination, appear to provide the functional equivalent to the BAF180 protein. Each of these subunits contains two BDs, with Rsc1 and Rsc2 also containing a BAH domain ( Figure 1B ). It is therefore feasible that studies in yeast may shed light on the question of what substrates are recognized by the BDs of BAF180. Presently, the specific binding targets of the Rsc1 and Rsc2 BDs in vivo are not well understood. Nevertheless, it has been shown that, whereas the first BD of both Rsc1 and Rsc2 is largely dispensable, the second BD of both proteins is required for function [11] .
To date, there has been one scientific report on the in vitro binding specificity of the BDs from Rsc1 and Rsc2 (as well as a number of other yeast BDs [12] ). Interestingly, all four BDs from Rsc1 and Rsc2 displayed extremely weak binding to any of the acetyl-lysine-containing peptides tested and were all classified as 'non-binders' [12] . It is possible that there are other acetylated histone residues that are the true targets of these BDs, or in fact that they bind to other, non-histone acetylproteins. Nevertheless, this leaves the question of defining the binding targets of the four BDs from Rsc1 and Rsc2 unresolved. In contrast, more is known about the BDs of Rsc4. It has been shown that the second BD (BD2) binds specifically to H3K14ac [13] . There is also genetic data to support the link with H3K14ac, suggesting that this is indeed the physiological target of Rsc4 BD2. Interestingly, the first BD (BD1) is known to bind to an acetylated residue present at the Nterminus of the protein (Rsc4 K25ac) [13] . The biological importance of this is highlighted by recent data showing the K25R mutant-containing strain has problems dealing with replicative stress [14] . Given the homology of Rsc4 with BAF180, it is interesting to speculate that binding to these targets might also be functionally conserved within two of the BAF180 BDs.
Cancer-linked mutations found in the BDs of BAF180
The gene encoding BAF180 (PBRM1) is an essential gene in mice, and functions to promote embryonic coronary development and cardiac chamber maturation [15, 16] . PBRM1 was also recently identified in a screen looking for tumour suppressor genes in breast cancer [17] , and BAF180 protein expression levels varied in an analysis of different cancer cell lines [18] . As described above, PBRM1 was recently found to be mutated in a very high percentage of renal cell carcinomas [6] , thereby identifying PBRM1 as a major gene involved in renal cancer.
BAF180 and another PBAF-specific subunit, BRD7, were identified in a screen for genes important for prevention of faulty senescence, and when disrupted were found to promote proliferation [19] . The authors found that, consistent with a previous report [17] , p53 transcriptional activity is dependent on BAF180, providing a mechanism by which loss of BAF180 may lead to the onset of cancer. Moreover, gene expression analysis in cells before and after PBRM1 knockdown identified gene sets involved in chromosomal instability and proliferation [6] . One possibility is therefore that the function of the six BDs is to target BAF180, and consequently the PBAF chromatin remodelling complex, to promoters of gene sets involved in promoting genome stability and prevention of cellular proliferation.
In addition to transcriptional regulation of genes involved in genome stability and proliferation, a more direct role for BAF180 in mediating DNA repair may also exist. Although no published studies have specifically investigated the role of BAF180 in DNA damage responses, subunits common to both BAF and PBAF (the SWI/SNF core complex) have been studied and found to be recruited to sites of DNA damage [20] [21] [22] . Impaired DNA damage responses would therefore also provide a possible mechanism for tumorigenesis. Since histone acetylation has been implicated in SWI/SNF recruitment to damaged chromatin [22, 23] , the BDs of BAF180 may well be involved in facilitating this relocalization.
The majority of the identified cancer-linked mutations result in the expression of a truncated protein product, consistent with loss of BAF180 function in these cells. Yet, interestingly, there are also a number of in-frame deletions and missense mutations, some of which are found in the BDs [6] (Figure 1 and Table 2 ).
Through a combination of techniques, including manual inspection of structures (where available), amino acid [24] , and the use of publically available webserver 'Site Directed Mutator' [25] , we were able to analyse and make predictions about the potential consequences of each mutation on the folding and stability of the BDs, within the context of the full-length protein.
Of the 13 mutations we analysed, seven were predicted to have either a 'slightly' or 'highly' destabilizing effect on the domain fold (Table 2) , which is consistent with the idea that the mutations of BAF180 found in cancer cells are functionally inactivating and therefore important drivers of tumorigenesis.
Potentially more interesting, however, are the mutations that are not predicted to globally perturb BD folding or stability, but that may nevertheless impair specific functions of BAF180. For example, the R540S mutation in BD4 is predicted to be neutral in terms of protein fold (Table 2) , but is located within the ZA loop of the BD, which is involved in acetyl-lysine binding ( Figure 2B ). This may therefore affect acetylated target protein binding affinity and/or specificity of this individual BD. Likewise, although predicted to have a slightly destabilizing effect, the G201V mutation in BD2 is also located within the acetyl-lysinebinding site, and may therefore only affect BD2 function in vivo. This raises the interesting possibility that inactivation of a single BD's binding capability is sufficient to disrupt at least a subset of BAF180 cellular functions.
Why so many BDs?
The dissociation constants determined for individual BDs binding to acetylated substrates are relatively low (i.e. in the micromolar range) and therefore could imply that they work co-operatively in vivo, to simultaneously bind to multiple, different or adjacent sites within chromatin [12] , with each having a distinct binding target. In this scenario, all six BDs would each contribute to chromatin binding. If true, one could assume that mutation of a single BD would not grossly affect the overall chromatin-binding affinity of the BAF180 protein. However, in addition to substrate binding, the six BDs may well also contribute to the overall three-dimensional architecture of BAF180 and/or the entire PBAF complex. In support of this idea, a recent report has shown that the presence of acetylated histone H3 peptides induce structural rearrangements in the PBAF-related complex RSC [26] . If so, disruption of one BD could be sufficient to completely impair PBAF function in vivo.
It is also feasible that not all BDs are needed and/or utilized in all situations. In this scenario, various different combinations of BDs could serve to function at promoter sequences (or at sites of DNA damage), depending on the pattern of chromatin modifications present in the local vicinity. Therefore a particular BD may only be required for binding to a subset of promoters that are regulated by BAF180.
Finally, it is possible that there is redundancy in the BDs of BAF180 and that not all of the BDs are necessary for function. Interestingly, the sixth BD of BAF180 is somewhat divergent from the others and does not contain either of the two highly conserved tyrosine residues (see Figure 2B ) that form an essential part of the acetyl-lysine-binding pocket. In addition, the ZA-loop adopts a non-canonical conformation, divergent to that seen for the five other BDs of BAF180. This suggests that BD6 is, in fact, not capable of binding to an acetyl-lysine target and is either functionally redundant, or specifically adapted to perform an alternative cellular function. Characterization of proteins and cell lines containing non-destabilizing mutations in individual BDs will begin to address these possibilities.
The potential complexity provided by the six BDs makes analysis of the mechanistic role of BAF180 in cells less than straightforward, and linking the function of BAF180 to its role in preventing tumorigenesis remains a challenge. However, it also raises interesting questions about modularity and specificity in chromatin-binding proteins, and with so many domains, provides an excellent system to study.
